Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prazosin Use in Adults With Anxiety Disorders
NCT03894345 · University of Manitoba · PHASE1 · suspended · last registry update 2022-11-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID-19” | – | Registry record, University of Manitoba |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-02Results posted on the registry: Indiana University, Antidepressant Medications (NCT04437485)
- 2023-10-25Phase 3 first posted: Humanitas Clinical and Research Center, Cannabidiol and β-Caryophyllene Patch (NCT06099171)
- 2023-10-16Phase 3 first posted: University of Aarhus, Noradrenalin + Phenylephrine (NCT06083948)
- 2023-08-21Results posted on the registry: Tulane University School of Medicine, amlodipine, hydralazine, terazosin or hydrochlorothiazide (NCT02046395)
- 2023-08-14Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% (NCT04620213)
- 2023-08-09Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (Placebo) (NCT04638660)
- 2023-08-02Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (NCT05223478)
- 2023-08-02Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Pilocarpine (NCT04675151)
- 2023-08-01Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (NCT05134974)
- 2023-07-24Results posted on the registry: Satsuma Pharmaceuticals, Inc., Dihydroergotamine + Placebo (NCT04940390)
- 2023-07-14Phase 3 first posted: Milton S. Hershey Medical Center, Oxymetazoline 0.1% (Pf) Oph Soln Ud (NCT05945615)
- 2023-07-12Results posted on the registry: Opus Genetics, Inc, Phentolamine Mesylate Ophthalmic Solution 1% (NCT03960866)
- 2023-07-05Phase 3 first posted: Odense University Hospital, Noradrenaline (NCT05931601)
- 2023-07-03Results posted on the registry: Satsuma Pharmaceuticals, Inc., Dihydroergotamine (NCT04406649)
- 2023-06-29Results posted on the registry: Satsuma Pharmaceuticals, Inc., Dihydroergotamine + Placebos (NCT03901482)
- 2023-04-10Also stopped (terminated): Johns Hopkins University, Prazosin (NCT04365257)
- 2023-04-04Also stopped (withdrawn): Montreal Heart Institute, Bromocriptine (NCT02590601)
- 2023-03-13Phase 3 first posted: DoCare Pharmaceutial Technology Co.,Ltd, Zihua Wenfei Zhisou Granule + Placebo (NCT05764668)
- 2023-02-22Phase 3 first posted: Ain Shams University, Epinephrine Inhalation Solution (NCT05738564)
- 2023-02-13Phase 3 first posted: Ain Shams University, Ephedrine + Rocuronium 0.6 (NCT05725031)
- 2023-02-06Results posted on the registry: Alzheimer's Disease Cooperative Study (ADCS), Prazosin + Placebo oral capsule (NCT03710642)
- 2023-02-03Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, prazosin hydrochloride + placebo (NCT02226367)
- 2023-01-31Phase 3 first posted: KIST Medical and Teaching Hospital, Intravenous bolus dose of Mephentermine and mephentermine + intravenous bolus dose of phenylephrine 50 mcg (NCT05706727)
- 2023-01-31Results posted on the registry: Johns Hopkins University, Prazosin (NCT04365257)
- 2023-01-09Results posted on the registry: Craig Rush, Methamphetamine + Methylphenidate (NCT04178993)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision